- Home
- OPI vs RANI Comparison
OPI vs RANI Comparison
Compare OPI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPI
- RANI
- Stock Information
- Founded
- OPI 2009
- RANI 2012
- Country
- OPI United States
- RANI United States
- Employees
- OPI N/A
- RANI N/A
- Industry
- OPI Real Estate Investment Trusts
- RANI Medicinal Chemicals and Botanical Products
- Sector
- OPI Real Estate
- RANI Health Care
- Exchange
- OPI Nasdaq
- RANI Nasdaq
- Market Cap
- OPI N/A
- RANI 55.3M
- IPO Year
- OPI 2009
- RANI 2021
- Fundamental
- Price
- OPI $0.46
- RANI $1.27
- Analyst Decision
- OPI Buy
- RANI Strong Buy
- Analyst Count
- OPI 2
- RANI 6
- Target Price
- OPI $4.30
- RANI $11.33
- AVG Volume (30 Days)
- OPI 1.1M
- RANI 147.7K
- Earning Date
- OPI 04-30-2025
- RANI 05-05-2025
- Dividend Yield
- OPI 8.79%
- RANI N/A
- EPS Growth
- OPI N/A
- RANI N/A
- EPS
- OPI N/A
- RANI N/A
- Revenue
- OPI $501,979,000.00
- RANI N/A
- Revenue This Year
- OPI N/A
- RANI N/A
- Revenue Next Year
- OPI N/A
- RANI N/A
- P/E Ratio
- OPI N/A
- RANI N/A
- Revenue Growth
- OPI N/A
- RANI N/A
- 52 Week Low
- OPI $0.44
- RANI $1.24
- 52 Week High
- OPI $3.02
- RANI $8.75
- Technical
- Relative Strength Index (RSI)
- OPI 23.02
- RANI 37.10
- Support Level
- OPI $0.48
- RANI $1.30
- Resistance Level
- OPI $0.94
- RANI $1.56
- Average True Range (ATR)
- OPI 0.08
- RANI 0.09
- MACD
- OPI -0.02
- RANI -0.02
- Stochastic Oscillator
- OPI 4.33
- RANI 16.06
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.